MA34878B1 - Utilisation de ligands sigma pour la douleur des cancers des os - Google Patents

Utilisation de ligands sigma pour la douleur des cancers des os

Info

Publication number
MA34878B1
MA34878B1 MA36072A MA36072A MA34878B1 MA 34878 B1 MA34878 B1 MA 34878B1 MA 36072 A MA36072 A MA 36072A MA 36072 A MA36072 A MA 36072A MA 34878 B1 MA34878 B1 MA 34878B1
Authority
MA
Morocco
Prior art keywords
bone cancer
cancer pain
sigma ligands
sigma
ligand
Prior art date
Application number
MA36072A
Other languages
English (en)
Inventor
Daniel Zamanillo-Castanedo
José Miguel Vela-Hernández
Carlos Plata-Salaman
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA34878B1 publication Critical patent/MA34878B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE L'UTILISATION D'UN LIGAND SIGMA, PARTICULIÈREMENT UN LIGAND SIGMA DE FORMULE (I) POUR PRÉVENIR ET/OU TRAITER LA DOULEUR ASSOCIÉE À UN CANCER DES OS.
MA36072A 2010-12-03 2011-12-02 Utilisation de ligands sigma pour la douleur des cancers des os MA34878B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382330A EP2460519A1 (fr) 2010-12-03 2010-12-03 Utilisation de ligands sigma pour la douleur du cancer des os
PCT/EP2011/071584 WO2012072782A1 (fr) 2010-12-03 2011-12-02 Utilisation de ligands sigma pour la douleur des cancers des os

Publications (1)

Publication Number Publication Date
MA34878B1 true MA34878B1 (fr) 2014-02-01

Family

ID=43629676

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36072A MA34878B1 (fr) 2010-12-03 2011-12-02 Utilisation de ligands sigma pour la douleur des cancers des os

Country Status (33)

Country Link
US (1) US20130324535A1 (fr)
EP (2) EP2460519A1 (fr)
JP (1) JP6027014B2 (fr)
KR (1) KR101855358B1 (fr)
CN (1) CN103313709B (fr)
AR (1) AR084730A1 (fr)
BR (1) BR112013013369A8 (fr)
CA (1) CA2819442C (fr)
CO (1) CO6781549A2 (fr)
CY (1) CY1119030T1 (fr)
DK (1) DK2646025T3 (fr)
ES (1) ES2626672T3 (fr)
HR (1) HRP20170818T1 (fr)
HU (1) HUE033488T2 (fr)
IL (1) IL226706A (fr)
LT (1) LT2646025T (fr)
MA (1) MA34878B1 (fr)
ME (1) ME02852B (fr)
MX (1) MX343773B (fr)
MY (1) MY171994A (fr)
NZ (1) NZ612119A (fr)
PL (1) PL2646025T3 (fr)
PT (1) PT2646025T (fr)
RS (1) RS56081B1 (fr)
RU (1) RU2585095C2 (fr)
SG (1) SG190745A1 (fr)
SI (1) SI2646025T1 (fr)
TN (1) TN2013000227A1 (fr)
TR (1) TR201708567T4 (fr)
TW (1) TWI629060B (fr)
UA (1) UA112638C2 (fr)
WO (1) WO2012072782A1 (fr)
ZA (1) ZA201304966B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (fr) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2353598A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
EP2353591A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance
EP2388005A1 (fr) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie
EP2415471A1 (fr) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes
EP2426111A1 (fr) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. Formes cristallines de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
EP2524694A1 (fr) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans la douleur liée au diabète de type 2
EP2792352A1 (fr) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Combinaisons comprenants un ligand de receptor Sigma et un ligand de réceptor adrénergic-alpha-2
EP2818166A1 (fr) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Utilisation de ligands des récepteurs sigma pour la prévention et le traitement de la douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (IC/BPS)
CN105611925A (zh) * 2013-09-12 2016-05-25 埃斯蒂维实验室股份有限公司 NSAID与σ受体配体的组合物
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations
US20160310501A1 (en) 2013-12-17 2016-10-27 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
EP2929883A1 (fr) * 2014-04-08 2015-10-14 Institut Pasteur Dérivés du pyrazole en tant qu'inhibiteurs de la dihydrooratate déhydrogénase (DHODH)
AR109024A1 (es) * 2016-07-12 2018-10-17 Esteve Labor Dr Uso de ligandos del receptor sigma en el dolor post-herpético
EP3796929A1 (fr) * 2018-05-21 2021-03-31 Ipsen Biopharm Limited Suppression de l'allodynie induite par le cancer des os
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
KR20210151572A (ko) 2020-06-05 2021-12-14 주식회사 허밍아비스 발열체 조성물 및 이를 이용한 마스크 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4838121B2 (ja) * 2003-06-26 2011-12-14 ノバルティス アーゲー ５員ヘテロ環を基礎とするｐ３８キナーゼ阻害剤
PL1781618T3 (pl) * 2004-08-27 2013-03-29 Esteve Labor Dr Inhibitory receptora sigma
DK1781618T3 (da) * 2004-08-27 2012-10-29 Esteve Labor Dr Sigma-receptorinhibitorer
WO2007098953A1 (fr) * 2006-03-01 2007-09-07 Laboratorios Del Dr. Esteve, S.A. Derives pyrazole utilises en tant qu'inhibiteurs du recepteur sigma
EP2113501A1 (fr) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. Pyrazoles de 5-Methyl-1-(naphthalen-2-YL)-1H- utiles en tant qu'inhibiteurs de récepteur sigma
EP2116539A1 (fr) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2353591A1 (fr) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance

Also Published As

Publication number Publication date
PT2646025T (pt) 2017-06-26
HUE033488T2 (en) 2017-12-28
CA2819442A1 (fr) 2012-06-07
BR112013013369A8 (pt) 2018-01-09
HRP20170818T1 (hr) 2017-08-25
JP6027014B2 (ja) 2016-11-16
ME02852B (fr) 2018-04-20
EP2646025A1 (fr) 2013-10-09
UA112638C2 (uk) 2016-10-10
RU2013130222A (ru) 2015-01-10
CN103313709A (zh) 2013-09-18
AR084730A1 (es) 2013-06-05
TR201708567T4 (tr) 2019-01-21
KR20130135881A (ko) 2013-12-11
IL226706A (en) 2015-07-30
PL2646025T3 (pl) 2017-09-29
ZA201304966B (en) 2014-09-25
ES2626672T3 (es) 2017-07-25
AU2011334880A1 (en) 2013-07-11
TW201249805A (en) 2012-12-16
SI2646025T1 (sl) 2017-07-31
MX343773B (es) 2016-11-23
DK2646025T3 (en) 2017-06-06
AU2011334880B2 (en) 2016-09-15
SG190745A1 (en) 2013-07-31
RU2585095C2 (ru) 2016-05-27
JP2014501732A (ja) 2014-01-23
LT2646025T (lt) 2017-06-12
MX2013006140A (es) 2013-07-03
RS56081B1 (sr) 2017-10-31
CA2819442C (fr) 2018-06-12
MY171994A (en) 2019-11-11
BR112013013369A2 (pt) 2016-09-06
TN2013000227A1 (en) 2014-11-10
EP2460519A1 (fr) 2012-06-06
NZ612119A (en) 2014-06-27
CN103313709B (zh) 2017-05-24
US20130324535A1 (en) 2013-12-05
CY1119030T1 (el) 2018-01-10
KR101855358B1 (ko) 2018-05-04
TWI629060B (zh) 2018-07-11
EP2646025B1 (fr) 2017-03-15
WO2012072782A1 (fr) 2012-06-07
CO6781549A2 (es) 2013-10-31

Similar Documents

Publication Publication Date Title
MA34878B1 (fr) Utilisation de ligands sigma pour la douleur des cancers des os
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
GEP20217281B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
MA34506B1 (fr) Utilisation de ligands sigma dans une hyperalgie induite par des opioides
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EA201171367A1 (ru) Винилиндазолильные соединения
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
TW200716141A (en) Compositions and methods for treatment for neoplasms
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
UA108631C2 (xx) Радіоімунокон'югати та їх застосування
SI1831209T1 (sl) Zaviralci fosfataz cdc25
EA201200247A1 (ru) Новые азагетероциклические соединения
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
EA201170344A1 (ru) Азаиндольные ингибиторы iap
MA34827B1 (fr) Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes
MX2010001303A (es) Compuestos terapeuticos.